Han Kun advises HighTide Therapeutics, Inc. on its listing on the Main Board of the Stock Exchange of Hong Kong
December, 2023 - Beijing, Mainland China
Han Kun Law Offices has advised and acted as PRC counsel to the company in connection with the global offering and listing of HighTide Therapeutics, Inc. 君圣泰医药 ("HighTide", Stock Code: 2511) on the Main Board of the Stock Exchange of Hong Kong Limited. This is yet another landmark project Han Kun has recently advised on in the biotechnology industry in relation to listing under Chapter 18A of the Hong Kong Listing Rules.
HighTide is a biopharmaceutical company specializing in the discovery, development, and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. HighTide's core product, HTD1801, a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
